Abstract: A use of an enhancer of rudimentary homolog (ERH) or a fragment thereof, in the preparation of a reagent for monitoring drug efficacy for rheumatoid arthritis, is provided. 35 proteins as candidate ACPA-negative RA autoantigens, 8 proteins as candidate autoantigens for predicting disease activity, and 6 proteins as candidate autoantigens for predicting treatment effect were screened by hybridizing high density protein chips with RA serum. Of the 6 proteins as candidate autoantigens for predicting treatment effect, one autoantigen, ERH, can successfully determine the effect of drug treatment on RA, and the AUC for predicting efficacy may be up to 0.733.

Abstract: The invention provides a use of a deoxyhypusine dioxygenase DOHH or a fragment thereof in the preparation of a reagent for diagnosing an anti-citrulline polypeptide antibody-negative rheumatoid arthritis disease. 35 proteins as candidate ACPA-negative RA autoantigens were screened by hybridizing high density protein chips with RA serum. 4 protein antigens (DOHH, DUSP11, PTX3 and PAGE5) were identified as having high sensitivity and specificity in the ACPA-negative serum of RA, wherein DOHH can be used as the ACPA-negative RA diagnostic markers.

Abstract: A use of a pentaxin-related protein 3 (PTX3) or a fragment thereof, in the preparation of a reagent for diagnosing an anti-citrulline polypeptide antibody-negative rheumatoid arthritis disease, is provided. 35 proteins as candidate ACPA-negative RA autoantigens were screened by hybridizing high density protein chips with RA serum. 4 protein antigens were identified as having high sensitivity and specificity in the ACPA-negative serum of RA, and all were newly discovered autoantigens (DOHH, DUSP11, PTX3, and PAGE5). The invention indicates that DOHH, DUSP11, PTX3, and PAGE5 can be used as ACPA-negative RA diagnostic markers.